GlassScriptPhysician profile
Lawrence Giove
NPI 1922360585
$6,737.77
in general payments reported to CMS, 2019-2025
45 companies · $975 in 2025
The $975 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,692 · 2020: $534 · 2021: $523 · 2022: $633 · 2023: $1,248 · 2024: $1,133 · 2025: $975.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,317 · Education: $38.53.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,316.60 |
| Education | $38.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $659.26 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $655.80 | 2019-2025 | Imfinzi, Tagrisso, Calquence |
| E.R. Squibb & Sons, L.L.C. | $566.57 | 2019-2025 | Opdivo, Augtyro |
| Novartis Pharmaceuticals Corporation | $456.69 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $450.79 | 2019-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Abbvie INC. | $331.31 | 2019-2025 | |
| Janssen Biotech, INC. | $317.52 | 2019-2025 | Carvykti, Rybrevant |
| Rigel Pharmaceuticals, INC. | $301.23 | 2023-2025 | Rezlidhia, Tavalisse, Tavalisse |
| Celgene Corporation | $291.92 | 2019-2024 | Pomalyst, Opdualag |
| Gilead Sciences, INC. | $282.23 | 2019-2025 | Trodelvy |
| Stemline Therapeutics INC. | $248.39 | 2023-2024 | Orserdu |
| Genentech USA, INC. | $246.97 | 2019-2023 | Polivy, Lunsumio, Columvi |
| Adc Therapeutics America, INC. | $153.66 | 2023-2025 | |
| Seagen INC. | $129.48 | 2019-2023 | Tukysa, Adcetris |
| Array Biopharma INC | $128.88 | 2023-2025 | Mektovi, Braftovi, Lorbrena |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Giove listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.